Evidence map›Paper›PMID 34031663›Full record

ArticlemedRxiv : the preprint server for health sciences2021

Detection of Antibody Responses against SARS-CoV-2 in Plasma and Saliva from Vaccinated and Infected Individuals.

Jéromine Klingler, Gregory S Lambert, Vincenza Itri, Sean Liu, Juan C Bandres, Gospel Enyindah-Asonye, Xiaomei Liu, Viviana Simon, Charles R Gleason, Giulio Kleiner and 8 more

Open access · greenAbstract readPreprint
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 10 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors at 2 institutions in 1 country.

Jéromine KlinglerDivision of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Gregory S LambertDivision of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Vincenza ItriDivision of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Sean LiuDivision of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Juan C BandresDivision of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Gospel Enyindah-AsonyeDivision of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Xiaomei LiuDivision of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Viviana SimonDivision of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Charles R GleasonDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Giulio KleinerDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Hsin-Ping ChiuDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Chuan-Tien HungDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Shreyas KowdleDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Fatima AmanatDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Benhur LeeDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Susan Zolla-PaznerDivision of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Chitra UpadhyayDivision of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Catarina E HioeDivision of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Icahn School of Medicine at Mount Sinai · USJames J. Peters VA Medical Center · US

Funding

COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTER: UNIVERSAL INFLUENZA VACCINE RESEARCH75N93019C00051 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI KRAMMER, FLORIAN · 2019 to 2025
$105.4M
DYNAMICS AND EVOLUTION OF IMMUNE RESPONSES TO INFLUENZA VIRUSESU01AI150747 · NIAID · EMORY UNIVERSITY · PI AHMED, RAFI, ANTIA, RUSTOM NOSHIR · 2020 to 2024
$5.9M
Programming Durable Immune Responses To VaccinationU01AI141990 · NIAID · WASHINGTON UNIVERSITY · PI Ali Hassan Ellebedy · 2019 to 2026
$5.3M
Harnessing Abs specific for immunogenic and conserved Env epitopes to protect against HIVR01AI139290 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI HIOE, CATARINA E · 2018 to 2022
$4.1M
Modulating antigenic and immunogenic properties of HIV Env by altering signal sequenceR01AI140909 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI UPADHYAY, CHITRA · 2019 to 2023
$3.3M
Tropism, pathogenicity, and potential for zoonotic spillover of emergent henipa- and henipa-like virusesR01AI123449 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI LEE, BENHUR · 2016 to 2020
$2.7M
Human Parainfluenza Virus 3 Infection in a Novel Human Lung Tissue ModelR21AI149033 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI LEE, BENHUR, LIM, JEAN KYOU · 2020 to 2021
$463k
Metabolic and Immune Consequences of Antibiotic-Related Microbiome Alterations during TB TreatmentR21AI148033 · NIAID · NORTHWESTERN UNIVERSITY · PI MAIGA, MAMOUDOU · 2019 to 2020
$440k
Understanding Th-monocyte interactions in HIV infectionI01BX003860 · VA · JAMES J PETERS VA MEDICAL CENTER · PI HIOE, CATARINA E · 2018 to 2021
–
BLR&D Research Career Scientist Award ApplicationIK6BX004607 · VA · JAMES J PETERS VA MEDICAL CENTER · PI HIOE, CATARINA E · 2019 to 2025
–
BLRD VA I01 BX003860BLRD VA IK6 BX004607NIAID NIH HHS 75N93019C00051NIAID NIH HHS HHSN272201400006CNIAID NIH HHS HHSN272201400008CNIAID NIH HHS R01 AI123449NIAID NIH HHS R01 AI139290NIAID NIH HHS R01 AI140909NIAID NIH HHS R21 AI148033NIAID NIH HHS R21 AI149033NIAID NIH HHS U01 AI141990NIAID NIH HHS U01 AI150747
6 · The paper itself

Abstract

Antibodies (Abs) are essential for the host immune response against SARS-CoV-2, and all the vaccines developed so far have been designed to induce Abs targeting the SARS-CoV-2 spike. Many studies have examined Ab responses in the blood from vaccinated and infected individuals. However, since SARS-CoV-2 is a respiratory virus, it is also critical to understand the mucosal Ab responses at the sites of initial virus exposure. Here, we examined plasma versus saliva Ab responses in vaccinated and convalescent patients. Although saliva levels were significantly lower, a strong correlation was observed between plasma and saliva total Ig levels against all SARS-CoV-2 antigens tested. Virus-specific IgG1 responses predominated in both saliva and plasma, while a lower prevalence of IgM and IgA1 Abs was observed in saliva. Antiviral activities of plasma Abs were also studied. Neutralization titers against the initial WA1 (D614G), B.1.1.7 (alpha) and B.1.617.2 (delta) strains were similar but lower against the B.1.351 (beta) strain. Spike-specific antibody-dependent cellular phagocytosis (ADCP) activities were also detected and the levels correlated with spike-binding Ig titers. Interestingly, while neutralization and ADCP potencies of vaccinated and convalescent groups were comparable, enhanced complement deposition to spike-specific Abs was noted in vaccinated versus convalescent groups and corresponded with higher levels of IgG1 plus IgG3 among the vaccinated individuals. Altogether, this study demonstrates the detection of Ab responses after vaccination or infection in plasma and saliva that correlate significantly, although Ig isotypic differences were noted. The induced plasma Abs displayed Fab-mediated and Fc-dependent functions with comparable neutralization and ADCP potencies, but a greater capacity to activate complement was elicited upon vaccination.

Indexed as

ADCPantibody isotypescomplement fixationCOVID-19neutralizationsalivaSARS-CoV-2vaccination

Identifiers

PMID34031663
PMCPMC8142663
OpenAlexW3162989089

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.